February 24, 2013European Journal of Cardio-Thoracic Surgery
The transaortic approach for transcatheter aortic valve implantation: a valid alternative to the transapical access in patients with no peripheral vascular option. A single center experience†
Key result
Transaortic TAVI yields ~7% 30-day mortality in patients with unfavorable peripheral access.
- n=94
Why the study?
Transapical TAVI in patients with poor peripheral vessels is sometimes not feasible and associated with myocardial damage, bleeding, and other complications, prompting evaluation of the transaortic approach.
Population
94 consecutive patients with unfavorable peripheral access undergoing TAVI
Comparison
Transaortic TAVI approach as alternative to transapical access
Design
Single-center cohort study
Authors
Discussion
Loading...
Member takes
Overview
Offers benchmark outcomes for transaortic TAVI in poor peripheral access; leaves open randomized comparisons with alternative routes.
Study Design
Type
Cohort (n=94)
Multicenter
No
Structured PICO
P
Population
94 consecutive patients (mean age 84.1 years) with unfavorable peripheral access undergoing transaortic transcatheter aortic valve implantation.
E
Exposure
Transaortic (TAo) TAVI using Sapien XT (88.3%) or CoreValve (11.7%).
O
Outcome
Efficacy and safety according to VARC criteria (including device success, 30-day mortality, and combined safety endpoint).safety
The transaortic approach for TAVI is a feasible and safe alternative for patients with unfavorable peripheral access, achieving high device success and acceptable 30-day outcomes.
Cite This Study
Hayashida et al. (2013) conducted a cohort in Aortic valve disease with unfavorable peripheral access (n=94). Transaortic (TAo) approach for TAVI was evaluated on Thirty-day mortality. The transaortic approach for transcatheter aortic valve implantation in patients with unfavorable peripheral access resulted in a 30-day mortality of 7.4% and a combined safety endpoint of 16.0%.